Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Regeneron Pharmaceuticals Inc. closed $66.17 short of its 52-week high ($1,211.20), which the company reached on August 27th.

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Tectonic Therapeutic (TECX – Research Report) today. The company’s ...

The Family and Medical Leave Act does not require employers to allow qualified employees to work remotely. While such ...

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected ...

Dupilumab significantly reduced severe asthma exacerbations and SCS prescriptions vs omalizumab in patients using add-on maintenance therapy.

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

However, he sees opportunities outside of the GLP-1 landscape, pointing specifically to Regeneron (REGN) and Vertex (VRTX) as prime examples. Vertex, a leader in cystic fibrosis research, makes up ...